News

Van Leeuwenhoeck Institute initiates equity analyst coverage

Based on NPV based valuation, we believe that Cynata Therapeutics is substantially undervalued at the current share price of AUD 0.57. Using our valuation model and taking into account the future revenues from its Cymerus™ platform, the company’s current total value should be AUD 150-175 million, or AUD 1.67-1.95 per share

Download Report

More Information:  http://www.leeuwenhoeck.com/page2.html